A Study of LY3322207 in Healthy Participants and in Participants With Hypertension (High Blood Pressure)

Summary

The purpose of this study is to investigate the safety of the study drug known as LY3322207. Participants must be healthy or must have hypertension (high blood pressure). Participants with hypertension may already be taking a common drug to reduce blood pressure called an angiotensin-converting enzyme inhibitor (ACE-I) or an angiotensin II receptor blocker (ARB).

Timeline

Start

2018-07-13

Primary completion

2019-01-17

Completion

2019-01-17

Outcome

Outcome not reported

Stopped: “injection site reaction burden”

Drugs

Indications